News

Recommended dosage varies, but effectiveness increases with dosage, necessitating conclusive research.

Preston Klassen, MD, executive vice president of Arena Pharmaceuticals, discusses potential uses for etrasimod outside of inflammatory bowel disease

FDA approved addition of OS to labeling based on results of the ADMIRAL trial.

An assessment of the CanCOLD study showed that COPD exacerbations over 18 months were greater in patients with worse scores for sleep quality at baseline.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses olorinab's efficacy and safety for the treatment of abdominal pain in Crohn's disease.

The rare, chronic condition requires investigators to turn to unique registries and other patient populations to access therapy benefits.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses a post hoc analysis of biomarkers and clinical outcomes in patients with ulcerative colitis receving etrasimod.

Investigators found that patients receiving cariprazine showed significant improvement in cognitive symptoms compared to patients receiving aripiprazole or placebo therapy.

Women in medicine are making strides and publishing more papers than ever, despite an ongoing gender disparity.

A recent study from Brigham Young University introduced vaccine-hesitant students to survivors of the diseases that vaccines now can prevent.

Dysfunctional breathing is a common comorbidity in patients with severe asthma, and is associated with increased patient anxiety and depression.

BioMarin announced the investigative gene therapy reached pre-specified criteria for Factor VIII levels in adult patients with severe hemophilia A.

Allergan announced the FDA approved a New Drug Application for Vraylar for the treatment of depressive episodes associated with bipolar depression.

The first-in-class JAK1/JAK2 inhibitor from Incyte has become the first therapy to receive indication for these patients, which make up about half of the acute GVHD population.

Preston Klassen, MD, head of research and development at Arena Pharamaceuticals, discusses mucosal healing and histologic remission in patients with ulcerative colitis receiving etrasimod.

Steven Adelsheim, MD, discusses what he believes is the need to further recognize that many mental health conditions begin to develop at a young age.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

A new report from VHA shows synthetic opioids have accounted for a significant count of veteran deaths since 2010.

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

This is the first gene therapy approved for a devastating condition that leads to permanent ventilation or death for many patients by age 2.

Lori Raney, MD, of Health Management Associates in Colorado, sat down with us at APA 2019 to discuss how clinicians should address the mental health needs of an aging population.

Investigators presented data from a 2-year, open-label study into the efficacy and safety of lurasidone in children 10 to 17 years old at APA 2019.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

The real-world analysis of epicutaneous therapy for milk-related EoE progressively exposed pediatric patients to their milk allergen.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.